🔗 Permalink

Inventor profile of:

Cameron DURRANT

City:

Oxford, Florida

Country:

United States

Published Applications:

Last publication date:

2025-05-29

Top Assignees for applications by Cameron DURRANT

The entities that hold a legal rights for patent applications filed by inventor DURRANT Cameron:

Humanigen, Inc. 16 Burlingame, CA United States
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 4 Rochester, MN United States
HUMANIGEN, INC. 1 Short Hills, NJ United States
HUMANICEN, INC. 1 Burlingame, CA United States
HUMANIGEN, INC. 1 Burlingama, CA United States

Recent patent applications by DURRANT Cameron

Cameron DURRANT from Oxford, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-05-29

US20250171547A1

Chemistry; metallurgy

EPHA3 DIRECTED CAR-T CELLS FOR TREATMENT OF TUMORS

#2 | 2022-11-17

US20220363746A1

Chemistry; metallurgy

METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY

#3 | 2022-02-10

US20220040229A1

Human necessities

MATERIALS AND METHODS FOR TREATING CANCER

#4 | 2022-01-27

US20220025034A1

Chemistry; metallurgy

METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST

#5 | 2021-10-21

US20210322547A1

Human necessities

METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST

#6 | 2021-10-07

US20210309733A1

Chemistry; metallurgy

METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY

#7 | 2021-09-23

US20210290677A1

Human necessities

METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST

#8 | 2021-09-16

US20210284714A1

Chemistry; metallurgy

MATERIALS AND METHODS FOR TREATING CANCER

#9 | 2021-09-02

US20210269518A1

Chemistry; metallurgy

METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST

#10 | 2021-08-12

US20210246215A1

Chemistry; metallurgy

EphA3 directed CAR-T cells for treatment of tumors

#11 | 2021-07-29

US20210230262A1

Chemistry; metallurgy

METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST

#12 | 2021-05-06

US20210130488A1

Chemistry; metallurgy

METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST

#13 | 2020-11-12

US20200354443A1

Chemistry; metallurgy

Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab

#14 | 2019-11-07

US20190338023A1

Chemistry; metallurgy

Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab

#15 | 2019-10-24

US20190322735A1

Chemistry; metallurgy

Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist

#16 | 2019-09-19

US20190284271A1

Chemistry; metallurgy

Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity

#17 | 2019-06-27

US20190194343A1

Chemistry; metallurgy

Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist

InventorID:

2541512 ⎘